VANCOUVER, BC, April 19, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common…

Source

Previous articleBright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Next articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day